NuCana Plc (NCNA)
1.40
-0.03
(-2.10%)
USD |
NASDAQ |
Sep 04, 16:00
1.47
+0.07
(+5.00%)
After-Hours: 20:00
NuCana Research and Development Expense (Quarterly) : 3.020M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.020M |
| March 31, 2026 | 4.329M |
| December 31, 2025 | 2.309M |
| September 30, 2025 | 2.929M |
| June 30, 2025 | 9.484M |
| March 31, 2025 | 2.172M |
| December 31, 2024 | 0.9343M |
| September 30, 2024 | 4.857M |
| June 30, 2024 | 8.541M |
| March 31, 2024 | 8.600M |
| December 31, 2023 | 8.509M |
| September 30, 2023 | 9.414M |
| June 30, 2023 | 4.956M |
| March 31, 2023 | 8.268M |
| December 31, 2022 | 15.47M |
| September 30, 2022 | 8.683M |
| June 30, 2022 | 8.035M |
| Date | Value |
|---|---|
| March 31, 2022 | 12.67M |
| December 31, 2021 | 14.33M |
| September 30, 2021 | 12.36M |
| June 30, 2021 | 11.92M |
| March 31, 2021 | 12.00M |
| December 31, 2020 | 10.54M |
| September 30, 2020 | 7.901M |
| June 30, 2020 | 7.278M |
| March 31, 2020 | 7.587M |
| December 31, 2019 | 6.661M |
| September 30, 2019 | 5.972M |
| June 30, 2019 | 6.884M |
| March 31, 2019 | 5.665M |
| December 31, 2018 | 5.982M |
| September 30, 2018 | 4.344M |
| June 30, 2018 | 7.012M |
| March 31, 2018 | 5.156M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| Mereo BioPharma Group Plc | 1.811M |
| BioNTech SE | 514.38M |
| Silence Therapeutics Plc | 8.297M |
| Autolus Therapeutics Plc | 27.95M |